- United Kingdom
- /
- Pharma
- /
- LSE:KNB
Kanabo Group First Half 2024 Earnings: UK£0.003 loss per share (vs UK£0.003 loss in 1H 2023)
Kanabo Group (LON:KNB) First Half 2024 Results
Key Financial Results
- Revenue: UK£694.0k (up 55% from 1H 2023).
- Net loss: UK£1.75m (loss widened by 13% from 1H 2023).
- UK£0.003 loss per share (in line with 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Kanabo Group shares are up 4.2% from a week ago.
Risk Analysis
Before you take the next step you should know about the 5 warning signs for Kanabo Group (2 are significant!) that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if Kanabo Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About LSE:KNB
Kanabo Group
A digital health company, engages in the research, development and commercialization of cannabis-derived formulations and therapeutic inhalation devices.
Moderate with mediocre balance sheet.